[Zacks] - PDL BioPharma Inc. recently announced that it expects to generate third-quarter 2010 revenue of $86.0 million, representing an increase of 20% over the year-ago revenue of $71.4 million.
[Zacks] - PDL BioPharma Inc. recently announced that it expects to generate third-quarter 2010 revenue of $86.0 million, representing an increase of 20% over the year-ago revenue of $71.4 million.
[Zacks] - Biopharmaceutical company Repros Therapeutics Inc. recently announced that it intends to conduct a type B meeting with the US Food and Drug Administration regarding the phase III protocol for the company's lead pipeline candidate, Androxal.
[Zacks] - Eli Lilly and Company suffered a blow recently in the form of an unfavorable court ruling in its patent infringement case regarding Strattera.
[Zacks] - Incyte Corporation's second quarter 2010 earnings of 2 cents per share compared favorably with the loss of 41 cents in the year-ago period. Earnings in the reported quarter comfortably surpassed the Zacks Consensus Estimate of a loss of 4 cents.
NEW YORK (TheStreet) -- Expect more hostile deals in biotech and pharma as the M&A climate heats up, says Joel Papernik, an attorney at Mintz Levin. 2010 09 03 10:00
Wary China may review BHP's Potash bid. Nervous about market concentration, China may launch an antimonopoly probe into BHP Billiton's (BHP) $39B bid for Potash (POT), sources said. BHP, which declined to comment, is only seeking regulatory clearance in the U.S. and Canada. China is also said to be planning to review the merger of two Russian potash firms because of the impact these deals could have on the country, though it's...
Last Saturday, the New York Times ran a rather lengthy piece on the Alzheimer’s epidemic. The article came on the heels of the high-profile failure of Lilly’s (LLY) late-stage AD drug, Semagacestat.
As emerging markets continue to grow and affluence rises, the developing world is likely to be the driving force behind growth in the global health care sector, paving the path to opportunity in the iShares S&P Global Healthcare Sector Index Fund (IXJ), the iShares Dow Jones US Pharmaceuticals Index Fund (IHE) and the Vanguard Health Care ETF (VHT).
In a continued effort to expand the focus of my site's screens and hypothetical portfolios, this article is a fourth follow-up to an article written in early April focusing on the S&P 500 Dividend Aristocrats. The S&P 500 Dividend Aristocrats index measures the performance of large cap, blue chip companies within the S&P 500 that have followed a policy of increasing dividends every year for at least 25 consecutive years. The current list has 43 constituents.
If an investor wanted to replicate the list the best option is probably
As a long-term buy-and-hold investor, most of my evaluation efforts are aimed at determining when to buy a stock. Sometimes it is necessary to sell a stock and we need to be equally adept at identifying those times. I have stated on numerous occasions that I have one hard and fast sell rule for my individual dividend stocks: When an individual stock held as a dividend investment lowers its dividend, immediately sell it. However, there are other times it makes sense to sell. Consider these:
Investing these days for most people is like riding a roller coaster.You get on the ride,go way up and way down numerous times and at the end of the ride you find yourself back where you started and in some cases worse off, because you are sick to your stomach.
Investing does not have to be that way if you try to achieve "capital appreciation through capital preservation."
The genomics and proteomics revolution has produced thousands of new targets for drug discovery. Designing molecules with novel mechanisms is sexy and can be very rewarding but is risky and time consuming, though some would say this novelty and pursuit of innovation is the embodiment of the biotech industry. But the pursuit of innovation requires a large investment in research to define a target’s role in human biology, to validate its relevance in human disease. Even after this early validation, there is no guarantee that modulation of this target will result in an effective treatment in...
A Genzyme (GENZ) shareholder has filed suit to prevent the company from entering into an acquisition agreement with Sanofi-Aventis (SNY), The Boston Globe reported. Sanofi reportedly offered $69 a share or $18.4 billion to buy the Cambridge, Massachusetts-based biotech, although neither company has publicly commented on any offer or ongoing negotiations. The suit, filed in Superior Court in Woburn, Massachusetts, charges that selling the company to Sanofi at the price being discussed would be a breach of the Genzyme’s board fiduciary responsibility because it would represent a...
In the midst of a period of seemingly interminable gloom, two shafts of weak light appeared for Eli Lilly (LLY) last Thursday: an advisory committee partly backed expanded approval for Cymbalta and a judge temporarily blocked sales of generic versions of its hyperactivity therapy Strattera.
Both pieces of news come with caveats that lessen their shine, but as pressure seems to mount daily on Eli Lilly to demonstrate that it can navigate its way out of this dark spell, these small mercies come as some relief. Unfortunately, neither issue...
Despite a consensus-beating earnings report in July, investor pressure for stronger financial results has been unrelenting as Eli Lilly (LLY) approaches one of the steepest patent cliffs in the industry. An FDA advisory committee lent the company a ray of hope Thursday. It voted 8 to 6 in favor of recommending its blockbuster antidepressant, Cymbalta, be approved for the treatment of some types of chronic pain. But a string of disappointments preceding that result has turned up the heat.
INDIANAPOLIS, /PRNewswire via COMTEX News Network/ ? Eli Lilly and Company (NYSE: LLY) today announced that the US Court of Appeals for the Federal Circuit has affirmed a prior ruling by the US ...
Acrux has announced an impressive $A46.1 million maiden net profit for fiscal 2010, on revenue of $A56.1 million. Richard Treagus, who has led the biotechnology group since May 2006, has ...
By Goran Mijuk, Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Faced with austerity programs and health care reforms around the world, Roche Holding AG (ROG.VX) Friday launched its own cost-cutting ...
PDL BioPharma Inc. (NASDAQ:PDLI) recently announced that it expects to generate third-quarter 2010 (ending September 30) revenue of $86.0 million, representing an increase of 20% over the year-ago ...
Eli Lilly & Co. (LLY) [Chart - Analysis - News] gained some ground during trading yesterday, but it appears there is some bearish pressure building up in the background. Looking at yesterday's ...
By Jacob Bunge and Brendan Conway, Of DOW JONES NEWSWIRES Trading volume on Nasdaq OMX Group Inc.'s (NDAQ) PHLX options exchange jumped in August, though a rival attributed the gains to a ...
According to Sun Pharmaceutical Industries Ltd the USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for marketing of atomoxetine hydrochloride capsules ...
Sept. 1 (Bloomberg) -- Shares of the following companies may have unusual moves in US trading. Stock symbols are in parentheses. Burger King Holdings Inc. (BKC US): The fast-food chain is in talks ...
By Chip Brian Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $33.54 to a high of $34.04. Yesterday, the shares fell 1.12%, which took the trading range below the 3-day ...
NEW YORK (Market Intellisearch) -- Eli Lilly options saw high put activity today. A total of 6,962 put and 2,017 call contracts were traded raising a high Put/Call volume alert. Today's traded Put ...
Stock News 
